Earnings ·
Reports Q3 revenue of $90.4M and updates full-year Non-GAAP loss guidance to $46-$50M
FLGTFulgent Genetics, Inc.
Fulgent Genetics reported third-quarter 2026 revenue of $90.4 million, an approximately 8% increase year-over-year. The company posted a GAAP net loss of $13.2 million, or $(0.48) per share, and a Non-GAAP net loss of $2.4 million, or $(0.09) per share. Fulgent maintained its full-year revenue guidance at $330.0-$340.0 million but narrowed its outlook for the annual Non-GAAP loss to approximately $46.0-$50.0 million, reflecting disciplined spending across the business. The company ended the quarter with $652.4 million in cash and investments. Fulgent operates a technology-based genomic testing laboratory services business and develops therapeutic candidates for cancer treatment.